DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • Norway
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
AZT logo

ArcticZymes Technologies ASA Stock Price

OB:AZT Community·NOK 1.1b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 3 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

AZT Share Price Performance

NOK 21.50
-5.30 (-19.78%)
​
NOK 28.00
Fair Value
NOK 21.50
-5.30 (-19.78%)
23.2% undervalued intrinsic discount
NOK 28.00
Fair Value
Price NOK 21.50
AnalystConsensusTarget NOK 28.00
Wed, 29 Jul 26
Fair ValueNOK 28.00
Share Pricen/a

AZT Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value NOK 28 23.2% undervalued intrinsic discount

Precision Medicine Will Continue Advancing Through Biomanufacturing And Gene Therapies

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AZT logo
ArcticZymes Technologies
23.2% undervalued intrinsic discount

Precision Medicine Will Continue Advancing Through Biomanufacturing And Gene Therapies

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 29 Jul
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystConsensusTarget
AZT logo

AZT: New RNA Patent Will Support Future Biomanufacturing Upside

Fair Value: NOK 28 23.2% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Flawless balance sheet with reasonable growth potential.

0 Risks
2 Rewards
View Full Analysis

ArcticZymes Technologies ASA Key Details

NOK 133.4m

Revenue

NOK 6.1m

Cost of Revenue

NOK 127.3m

Gross Profit

NOK 111.9m

Other Expenses

NOK 15.4m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Nov 05, 2026
0.30
95.42%
11.54%
0%
View Full Analysis

About AZT

Founded
1990
Employees
51
CEO
Michael Akoh
WebsiteView website
www.arcticzymes.com

ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing. The company offers shrimp alkaline phosphatase; cod UNG for use in viral and other molecular diagnostic assays for the removal of contaminating dU-DNA; salt active nucleases for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other reagents; and double-strand specific DNases and derived kits for the removal of double stranded DNA. It also provides DNA/RNA polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; and ligases for joining nucleic acids. The company serves the molecular tools market, and biomanufacturing markets. It operates in Norway, Germany, Lithuania, France, Italy, the United Kingdom, rest of Europe, the United States, and internationally. The company was formerly known as Biotec Pharmacon ASA and changed its name to ArcticZymes Technologies ASA in June 2020. ArcticZymes Technologies ASA was founded in 1990 and is headquartered in Tromsø, Norway.

Recent AZT News & Updates

Analysis Article • Aug 18

ArcticZymes Technologies ASA Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Investors in ArcticZymes Technologies ASA ( OB:AZT ) had a good week, as its shares rose 3.1% to close at kr20.10...
User avatar
Narrative Update • Jul 29

AZT: New RNA Patent Will Support Future Biomanufacturing Upside

Analysts have trimmed their fair value estimate for ArcticZymes Technologies from NOK32 to NOK28. They point to more measured revenue growth expectations, slightly higher projected profit margins, and a lower future P/E assumption as the key drivers of the change in price target.

Recent updates

No updates

ArcticZymes Technologies ASA Competitors

CRNA logo

Circio Holding

Symbol: OB:CRNA
Market cap: NOK 3.6b
TRMED logo

Thor Medical

Symbol: OB:TRMED
Market cap: NOK 2.0b
PHO logo

Photocure

Symbol: OB:PHO
Market cap: NOK 1.4b
NYKD logo

Nykode Therapeutics

Symbol: OB:NYKD
Market cap: NOK 1.3b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide